Sanofi's type 1 diabetes drug recommended for EU approval

The European Medicines Agency's committee has recommended approval of French drugmaker Sanofi's first-of-its-kind drug that ...
The American Journal of Managed Care

Teplizumab Approved by FDA to Delay Type 1 Diabetes

The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes. The FDA Thursday approved teplizumab, the first drug to delay the onset of type 1 diabetes (T1D). Teplizumab, a ...
Medscape

EMA Backs Preventive Therapy for Stage 3 Type 1 Diabetes

The recommendation follows results showing markedly longer time to diagnosis of stage 3 T1D in treated patients, a condition ...
The American Journal of Managed Care

Teplizumab Studies Lead to Important Update in ADA Living Standards of Care

The American Diabetes Association's chief scientific and medical officer said the results are important to families at risk of type 1 diabetes. Recent studies involving teplizumab, which is currently ...
Pharmabiz

EMA recommends marketing authorisation to Sanofi Winthrop Industrie’s Teizeild to delay onset of type 1 diabetes

EMA recommends marketing authorisation to Sanofi Winthrop Industrie’s Teizeild to delay onset of type 1 diabetes: Amsterdam, The Netherlands Saturday, November 15, 2025, 11:00 H ...
Hosted on MSN

Sanofi’s Teplizumab Study: A Closer Look at Real-World Impact on Type 1 Diabetes

Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced ...
Monthly Prescribing Reference

Teplizumab BLA for T1D Prevention Submitted

type 1 diabetes The BLA is supported by data from a phase 2 trial that evaluated whether teplizumab could prevent or delay the onset of T1D in at-risk individuals. The Biologics License Application ...
Healio

Teplizumab preserves beta-cell function for children with new-onset type 1 diabetes

Please provide your email address to receive an email when new articles are posted on . Children recently diagnosed with type 1 diabetes had a higher C-peptide level at 78 weeks with teplizumab vs.
Healio

Teplizumab temporarily protects against type 1 diabetes in high-risk individuals

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN FRANCISCO — Those who are most likely ...
Nasdaq

Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway

RED BANK, N.J., Nov. 22, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an ...
Monthly Prescribing Reference

FDA Panel Votes on Teplizumab for the Delay of Type 1 Diabetes

type 1 diabetes Teplizumab is an investigational anti-CD3 monoclonal antibody. The Food and Drug Administration (FDA)’s Endocrinologic and Metabolic Drugs Advisory Committee voted 10 yes and 7 no on ...
Medscape

Teplizumab Preserves Beta Cells in New-Onset Type 1 Diabetes

Teplizumab (Tzield) infusions in children and adolescents with new-onset type 1 diabetes met the primary endpoint of preserved beta-cell function and trended toward improved secondary glycemic ...